Clinical drug–drug interaction studies investigating pharmacokinetics and safety of sevabertinib
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/hupz6671 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Barbara J. Brennan und 13 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Sevabertinib (BAY 2927088) is an oral reversible tyrosine kinase inhibitor being developed for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer harboring human epidermal growth factor receptor 2–activating mutations. Three clinical drug–drug interaction studies with sevabertinib were performed to investigate the effects of: (1) the CYP3A4/P-glycoprotein (P-gp) inhibitor itraconazole and the CYP3A4/P-gp inducer carbamazepine on the pharmacokinetics (PK) of sevabertinib (NCT06348888); (2) sevabertinib on the PK of the CYP3A4 substrate midazolam (NCT06360211); and (3) sevabertinib on the PK of the P-gp substrate dabigatran etexilate and the breast cancer resistance protein (BCRP) substrate rosuvastatin (NCT06329895).
Zitieren
APA
Brennan, B. J., Uddin, A., Damaske, M., Hafner, F., Fricke, R., Piel, I., Buehler, C. V., Niehues, M., Jungmann, N., Reif, S., Prendergast, S., Lienau, P., Ploeger, B., & Chen, C. (2026). Clinical drug–drug interaction studies investigating pharmacokinetics and safety of sevabertinib. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/hupz6671
Vancouver
Brennan BJ, Uddin A, Damaske M, Hafner F, Fricke R, Piel I, et al. Clinical drug–drug interaction studies investigating pharmacokinetics and safety of sevabertinib. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/hupz6671
BibTeX
@article{Brennan2026,
author = {Brennan, Barbara J. and Uddin, Alissa and Damaske, Michaela and Hafner, Frank-Thorsten and Fricke, Robert and Piel, Isabel and Buehler, Clemens-Jeremias von and Niehues, Michael and Jungmann, Natalia and Reif, Stefanie and Prendergast, Sue and Lienau, Philip and Ploeger, Bart and Chen, Chunlin},
title = {Clinical drug–drug interaction studies investigating pharmacokinetics and safety of sevabertinib},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/hupz6671}
}
EUVIMED